Loading company…
Versa Vascular develops minimally invasive devices for tricuspid valve repair.
Founded in 2020 and based in Santa Cruz, US, Versa Vascular develops treatments for clinically significant tricuspid regurgitation. Its Versa Implant is designed for placement in the right atrium while preserving native leaflet function, with a delivery system that allows repositioning. CEO David Hovda leads the company. In August 2026, Versa Vascular raised USD 15 million in Series C funding from S3 Ventures and BioStar Capital to support studies and further development of its AdapTR technology.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in